Highlights

  • Orthocell recorded AUD 3.2 million in December quarter revenue, marking its seventh consecutive quarter of record revenue.
  • U.S. Remplir sales commenced with approximately AUD 90,000 generated in December and distributor coverage across 25+ states.
  • Cash reserves stood at AUD 49.4 million, with an expected AUD 3.0 million R&D tax incentive refund in FY26.

Orthocell Limited (ASX:OCC) has reported record quarterly revenue of AUD 3.2 million for the quarter ended 31 December 2025, marking its seventh consecutive quarter of record revenue. The result was supported by increased sales of the Remplir™ nerve repair product across existing markets and early contributions from the United States.

December Quarter Revenue Sets New High

Revenue for the December 2025 quarter increased 7.0% from the previous quarterly record of AUD 3.0 million reported in September 2025. Compared with the prior corresponding period, revenue rose 45.2%, extending the company’s run of consecutive quarterly revenue records.

Since Q3 FY24, Orthocell has achieved a compound quarterly growth rate (CQGR) of 10.4%, reflecting continued expansion in product sales. The December quarter result was primarily driven by higher Remplir sales in established markets, particularly Australia, along with initial U.S. revenue contributions.

Approximately AUD 90,000 in Remplir sales were generated in the United States during December, in line with expectations.

U.S. Commercialisation Progress

Orthocell continues to advance the commercial rollout of Remplir in the United States using a hybrid market entry model that combines specialist distributors with internal field leadership. The distributor network now covers more than 25 states, representing approximately 40% of the U.S. population.

During the quarter, 61 hospital Value Analysis Committee (VAC) applications were in progress, with 23 approvals granted ahead of schedule. The company also completed 11 major medical education meetings across key U.S. states, introducing surgeons to Remplir’s clinical application and workflow integration.

Early surgical cases in the U.S. contributed to December quarter revenue, with further adoption expected to build as hospital approvals and surgeon onboarding continue.

Canada Entry and International Expansion

Orthocell recently appointed a second distributor in Canada, expanding its commercial footprint in the region. Initial Canadian sales are targeted for the March quarter FY26, with market adoption expected to increase progressively through 2026.

The company’s international expansion strategy mirrors approaches previously implemented in Australia and Singapore, with a focus on distributor engagement, clinician education, and active account development.

Cash Position and Upcoming Reporting

As of 31 December 2025, Orthocell reported total cash reserves of AUD 49.4 million, comprising AUD 7.4 million in cash and cash equivalents and AUD 42.0 million in term deposits with maturities ranging from three to twelve months. The company also expects to receive an R&D tax incentive refund of approximately AUD 3.0 million in the March quarter FY26.

Orthocell plans to release its full Quarterly Activity Report and Appendix 4C by Friday, 23 January 2026.

Orthocell shares were trading at AUD 1.11, up AUD 0.013, representing a 1.14% increase.